Clinical Trials Logo

Laryngeal Diseases clinical trials

View clinical trials related to Laryngeal Diseases.

Filter by:

NCT ID: NCT03429036 Recruiting - Clinical trials for Head and Neck Neoplasms

Biospecimen Procurement for Head and Neck Disorders

Start date: May 23, 2018
Phase:
Study type: Observational

Background: Researchers want to learn more about head and neck disorders. Understanding these disorders could help them find better treatments. To do this, they are collecting tissue samples for research. Objective: To create a repository of tissue samples and data to better study conditions of the head and neck. Eligibility: People who had or will have tissue samples taken because of a head or neck disorder. They must be ages 3 and older and not pregnant to join Part 2. Design: Participants will be screened with a questionnaire, medical history, and physical exam. Part 1. Participants will give permission for any of their tissue samples leftover from private care or other research protocols to be used. If participants tissue did not contain normal tissue or if they have a condition that suggests a genetic issue, they will be invited to join Part 2. Part 2: Participants will have additional samples collected. These could be: - Blood: Blood is drawn through a needle in the arm. - Cheek swab or brushing: A cotton swab or small brush is rubbed inside the cheek. - Saliva: They rinse their mouth with water and spit into a tube or cup. - Skin biopsy: They are injected with a numbing drug. A biopsy tool removes a small piece of skin. - Mucosal biopsy: They are injected in the mouth with a numbing medication. A small piece of tissue from the inside of the cheek is removed. Participants samples will be used for future research, including genetic testing.

NCT ID: NCT03269396 Enrolling by invitation - Larynx Clinical Trials

Laryngeal Allograft Transplantation

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal allograft transplantation in an effort to safely use these procedures as a viable reconstructive option for patients with severe laryngeal or laryngotracheal incompetence.

NCT ID: NCT03214835 Withdrawn - Clinical trials for Laryngopharyngeal Reflux

CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will be recruited.

NCT ID: NCT02960243 Completed - Essential Tremor Clinical Trials

Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?

EVT
Start date: August 2016
Phase: N/A
Study type: Interventional

Deep Brain Stimulation (DBS) is the gold standard treatment for Essential Tremor (ET). ET is a movement disorder which causes the arms, feet, fingers, head or voice to involuntarily shake. The DBS surgical procedure involves implanting an electrode deep within the brain which blocks damaging signals that cause the tremor. Essential Voice Tremor (EVT) is the vocal manifestation of ET and a number of individuals have both ET and EVT, and when these patients are implanted for their ET, their EVT symptoms are often also mitigated. This study aims to quantify the effects of DBS on EVT by testing on these ET+EVT patients. In addition to this, we hope to determine which hemisphere of the brain is responsible for larynx control: left or right.

NCT ID: NCT02757222 Completed - Clinical trials for Malignant Neoplasm of Hypopharynx Stage IVa

Dose Escalation Versus Standard in Laryngopharyngeal Cancers

INTELHOPE
Start date: January 2016
Phase: N/A
Study type: Interventional

The primary objective of the study is to establish the safety of using a moderate escalation of radiotherapy dose in advanced/poor prognosis OPC and LH cancers receiving curative radiotherapy. The study will also explore the efficacy (improvement in complete response rates at 2 years) of dose escalation in intermediate and high risk OPC and LH cancers patients.

NCT ID: NCT02552225 Terminated - Laryngeal Diseases Clinical Trials

Treatment of Chronic Laryngitis With Amitriptyline

Start date: April 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled trial will compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis.

NCT ID: NCT02434523 Terminated - Laryngeal Diseases Clinical Trials

Trial of the Treatment of Chronic Laryngitis With Amitryptiline

Start date: September 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The study will compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis. At the baseline visit, subjects will be assigned at random to amitriptyline or placebo which they will take for 8 weeks. Subjects will be seen in the clinic at baseline and at 8 weeks. Improvement will be measured using standardized symptom scales, and a self-reported subjective improvement percentage.

NCT ID: NCT02245100 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

Start date: July 22, 2014
Phase:
Study type: Observational

This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer. Studying circulating tumor DNA from patients with head and neck or lung cancer in the laboratory may help doctors predict how well patients will respond to treatment.

NCT ID: NCT02177838 Terminated - Tongue Cancer Clinical Trials

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

Start date: March 25, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.

NCT ID: NCT02123511 Completed - Mucositis Clinical Trials

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Start date: April 2014
Phase: Phase 2
Study type: Interventional

This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy. Side effects from radiation therapy to the head and neck, such as thickened saliva and mouth sores, may interfere with activities of daily living such as eating and drinking, and may also cause treatment to be stopped or delayed. Acetylcysteine rinse may reduce saliva thickness and mouth sores, and improve quality of life in patients with head and neck cancer undergoing radiation therapy.